Microvascular disease in diabetes and severe COVID-19 outcomes - Authors' reply

Affiliations

¹ Institute of Genetics and Molecular Medicine, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK; Public Health Scotland, Glasgow, UK. Electronic address: helen.colhoun@igmm.ed.ac.uk.
² Institute of Genetics and Molecular Medicine, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK; Public Health Scotland, Glasgow, UK.
³ Public Health Scotland, Glasgow, UK; Usher Institute College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.

Comment

Helen M Colhoun et al. Lancet Diabetes Endocrinol. 2021 Apr.

. 2021 Apr;9(4):201.

doi: 10.1016/S2213-8587(21)00055-3.

¹ Institute of Genetics and Molecular Medicine, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK; Public Health Scotland, Glasgow, UK. Electronic address: helen.colhoun@igmm.ed.ac.uk.
² Institute of Genetics and Molecular Medicine, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK; Public Health Scotland, Glasgow, UK.
³ Public Health Scotland, Glasgow, UK; Usher Institute College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.

No abstract available

Comment on

Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland.
McGurnaghan SJ, Weir A, Bishop J, Kennedy S, Blackbourn LAK, McAllister DA, Hutchinson S, Caparrotta TM, Mellor J, Jeyam A, O'Reilly JE, Wild SH, Hatam S, Höhn A, Colombo M, Robertson C, Lone N, Murray J, Butterly E, Petrie J, Kennon B, McCrimmon R, Lindsay R, Pearson E, Sattar N, McKnight J, Philip S, Collier A, McMenamin J, Smith-Palmer A, Goldberg D, McKeigue PM, Colhoun HM; Public Health Scotland COVID-19 Health Protection Study Group; Scottish Diabetes Research Network Epidemiology Group. McGurnaghan SJ, et al. Lancet Diabetes Endocrinol. 2021 Feb;9(2):82-93. doi: 10.1016/S2213-8587(20)30405-8. Epub 2020 Dec 23. Lancet Diabetes Endocrinol. 2021. PMID: 33357491 Free PMC article. Clinical Trial.
Microvascular disease in diabetes and severe COVID-19 outcomes.
Corcillo A, Whyte MB, Vas P, Karalliedde J. Corcillo A, et al. Lancet Diabetes Endocrinol. 2021 Apr;9(4):200-201. doi: 10.1016/S2213-8587(21)00053-X. Lancet Diabetes Endocrinol. 2021. PMID: 33740436 Free PMC article. No abstract available.

1. McGurnaghan SJ, Weir A, Bishop J, et al. Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. Lancet Diabetes Endocrinol. 2021;9:82–93. - PMC - PubMed
1. Teuwen L-A, Geldhof V, Pasut A, Carmeliet P. COVID-19: the vasculature unleashed. Nat Rev Immunol. 2020;20:389–391. - PMC - PubMed
1. Chan NN, Vallance P, Colhoun HM. Endothelium-dependent and -independent vascular dysfunction in type 1 diabetes: role of conventional risk factors, sex, and glycemic control. Arterioscler Thromb Vasc Biol. 2003;23:1048–1054. - PubMed
1. Holman N, Knighton P, Kar P, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2020;8:823–833. - PMC - PubMed